UNSPSC 51161884: Sequifenadine

This classification denotes a serotonin antagonist and histamine-1 receptor antagonist with the molecular formula C22H27NO, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C7Q3TBR3FP, chemically known as 3-quinuclidinemethanol, alpha,alpha-di-o-tolyl- but more generally known as sequifenadine, which bears U.S. NIH Compound Identifier 42553. European Medicines Agency schedules Sequifenadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10488MIG.

The term SEQUIFENADINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). SEQUIFENADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51161884 Sequifenadine, a Commodity code, does not map to state and local procurement activity in the recent opportunities record. The code nominally identifies a specific pharmaceutical ingredient (sequifenadine, an antihistamine), yet the two most recent state and local solicitations posted under this code request parenteral products and services (parenteral nutrition, intravenous solutions, and controlled substances for correctional healthcare) and naloxone with drug deactivation systems (for community health initiatives). Neither solicitation involves sequifenadine procurement. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, closing October 7, 2026, for parenteral products, services, and equipment across eight facilities, with a pre-bid conference on September 23, 2026 and a five-percent small and diverse business goal; Seminole County, Florida released IFB 60459723LAS on June 30, 2026, closing July 26, 2023 (a date in the past relative to the source publication), for naloxone and drug deactivation systems with quarterly deliveries to a community health building. The mismatch between the code's pharmaceutical specificity and the actual solicitation scope suggests either a classification error in the state and local procurement databases or a code designation that does not reflect current buying practice under this UNSPSC category.

State and local procurement professionals evaluating opportunities under UNSPSC 51161884 should verify the code assignment directly with issuing bodies and consider whether the code correctly tags their target market. The recent opportunities show activity from a state department of corrections and a county health authority, but the pharmaceutical products actually being requested diverge significantly from sequifenadine. Without additional solicitation records or evidence that sequifenadine appears in the scope of work, this code presents limited visibility into genuine market demand.